aTyr Pharma (NASDAQ:ATYR) Rating Lowered to "Neutral" at Cantor Fitzgerald

Key Points

• aTyr Pharma has been downgraded from an "overweight" to a "neutral" rating by analysts at Cantor Fitzgerald.
• Despite the downgrade, the average rating for aTyr Pharma remains "Buy" with an average price target of $23.25, while Jefferies and Wells Fargo have set price targets of up to $25.00.
• The company's share price declined to $1.12 on Monday, with a significant trading volume of over 90 million shares.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) was downgraded by analysts at Cantor Fitzgerald from an "overweight" rating to a "neutral" rating in a research report issued on Monday,Briefing.com Automated Import reports.

ATYR has been the subject of several other research reports. Jefferies Financial Group boosted their price target on shares of aTyr Pharma from $9.00 to $17.00 and gave the company a "buy" rating in a report on Friday, August 22nd. Wells Fargo & Company boosted their price target on shares of aTyr Pharma from $17.00 to $25.00 and gave the stock an "overweight" rating in a research report on Friday, June 20th. Wall Street Zen lowered shares of aTyr Pharma from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. Finally, HC Wainwright reissued a "buy" rating and set a $35.00 target price on shares of aTyr Pharma in a research note on Wednesday, June 4th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, aTyr Pharma presently has an average rating of "Buy" and an average price target of $23.25.

aTyr Pharma Price Performance

Shares of NASDAQ ATYR traded down $4.92 on Monday, hitting $1.12. The company's stock had a trading volume of 90,193,160 shares, compared to its average volume of 3,126,573. aTyr Pharma has a 12-month low of $1.00 and a 12-month high of $7.29. The company has a market capitalization of $109.26 million, a price-to-earnings ratio of -1.42 and a beta of 1.01. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.63 and a quick ratio of 5.63. The stock has a 50 day moving average of $5.36 and a 200-day moving average of $4.39.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.04). As a group, research analysts predict that aTyr Pharma will post -0.91 EPS for the current year.

Institutional Investors Weigh In On aTyr Pharma

Institutional investors have recently modified their holdings of the business. Octagon Capital Advisors LP boosted its stake in aTyr Pharma by 7.5% during the 2nd quarter. Octagon Capital Advisors LP now owns 3,820,000 shares of the company's stock worth $19,367,000 after acquiring an additional 268,000 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of aTyr Pharma by 126.1% in the second quarter. Geode Capital Management LLC now owns 2,098,076 shares of the company's stock valued at $10,639,000 after buying an additional 1,170,276 shares during the period. Woodline Partners LP acquired a new position in shares of aTyr Pharma in the fourth quarter valued at approximately $6,092,000. Millennium Management LLC boosted its holdings in shares of aTyr Pharma by 334.5% in the first quarter. Millennium Management LLC now owns 1,599,041 shares of the company's stock valued at $4,829,000 after buying an additional 1,231,052 shares during the period. Finally, Ally Bridge Group NY LLC boosted its holdings in shares of aTyr Pharma by 11.0% in the first quarter. Ally Bridge Group NY LLC now owns 777,020 shares of the company's stock valued at $2,347,000 after buying an additional 77,290 shares during the period. Institutional investors and hedge funds own 61.72% of the company's stock.

About aTyr Pharma

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.